Inclusion Criteria:
  -  Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
  -  The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study
  -  Male or female, age greater than or equal to 18 years at the time of signing informed consent
  -  Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion
  -  Available and documented haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment
Exclusion Criteria:
  -  Previous participation in this study. Participation is defined as having given informed consent in this study
  -  Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  -  Treatment with any investigational drug within 90 days prior to enrolment into the study
  -  Hypersensitivity to semaglutide or to any of the excipients